Answers are grounded in this paper and cite their sources.
Chemotherapy resistance limits disease control in triple‑negative breast cancer (TNBC). The present narrative review examined how extracellular vesicle (EV)‑associated microRNAs (miRNAs/miR) affect drug responses and how far the evidence supports clinical development of EV‑miRNA biomarkers and EV‑based therapeutic strategies. Across the selected studies, miRNAs promote resistance or increase sensitivity depending on the drug, delivery route and cellular model. The review‑specific framework utilized in the present study distinguishes between a linked EV‑miRNA causal sequence in TNBC donor and recipient models (Tier 1), incomplete mechanistic attribution or evidence extrapolated from other models, cargoes or treatments (Tier 2) and associative findings (Tier 3). Tier 1, the highest tier in this review‑specific framework, requires EV‑associated miRNA enrichment, uptake, target engagement, a resistance phenotype and miRNA‑specific reversal or rescue. These categories are not validated measures of bias or clinical certainty. The accessible miR‑423‑5p evidence supports functional modulation but not a complete EV‑specific causal chain, and therefore was categorized as Tier 2. Circulating EV‑miRNA signatures remain exploratory biomarkers, and engineered miRNA or inhibitor delivery remains preclinical. RNA detection in an EV preparation alone does not establish intravesicular localization. Further development requires controls that attribute effects to transferred cargo, reproducible EV measurements and independent clinical validation.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: